zanamivir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals neuraminidase inhibitors 2859 139110-80-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zanamivir
  • relenza
  • zanamivir hydrate
A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.
  • Molecular weight: 332.31
  • Formula: C12H20N4O7
  • CLOGP: -5.56
  • LIPINSKI: 2
  • HAC: 11
  • HDO: 8
  • TPSA: 198.22
  • ALOGS: -2.35
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg Inhal.powder
1.20 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 36 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 100 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.86 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 2 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.23 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.86 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 26, 2019 EMA GlaxoSmithKline Trading Services Limited
July 26, 1999 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Exposure during pregnancy 590.16 42.45 204 1630 155343 63331845
Abnormal behaviour 386.29 42.45 95 1739 21331 63465857
Delivery 181.81 42.45 32 1802 1371 63485817
Hallucination 121.38 42.45 49 1785 54768 63432420
Overdose 120.73 42.45 61 1773 115017 63372171
Loss of consciousness 74.96 42.45 45 1789 118076 63369112
Delirium 68.51 42.45 32 1802 50509 63436679
No adverse event 58.53 42.45 27 1807 41378 63445810
Altered state of consciousness 47.07 42.45 20 1814 25210 63461978

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abnormal behaviour 1108.30 44.67 257 1655 24712 34930307
Hallucination 219.62 44.67 88 1824 51410 34903609
Delirium 139.52 44.67 61 1851 43930 34911089
Overdose 126.49 44.67 72 1840 90987 34864032
Aggression 88.77 44.67 43 1869 38921 34916098
Screaming 84.83 44.67 19 1893 1465 34953554
Restlessness 69.92 44.67 32 1880 25450 34929569
Amnesia 65.56 44.67 31 1881 26532 34928487
Crying 50.90 44.67 17 1895 5845 34949174
Hallucination, auditory 49.23 44.67 20 1892 11897 34943122
Depressed level of consciousness 49.04 44.67 30 1882 42811 34912208
Altered state of consciousness 48.27 44.67 24 1888 22869 34932150
Loss of consciousness 47.71 44.67 38 1874 82629 34872390

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abnormal behaviour 1024.48 39.98 236 2370 36185 79705597
Overdose 310.06 39.98 140 2466 184066 79557716
Hallucination 254.92 39.98 98 2508 85647 79656135
No adverse event 145.03 39.98 52 2554 37140 79704642
Delirium 128.03 39.98 60 2546 84567 79657215
Exposure via breast milk 108.52 39.98 20 2586 976 79740806
Exposure during pregnancy 86.83 39.98 49 2557 101083 79640699
Screaming 71.15 39.98 18 2588 3915 79737867
Pathogen resistance 67.11 39.98 23 2583 14319 79727463
Loss of consciousness 59.76 39.98 47 2559 167896 79573886
Restlessness 55.25 39.98 28 2578 46464 79695318
Aggression 50.01 39.98 27 2579 50931 79690851
Altered state of consciousness 42.38 39.98 23 2583 43799 79697983
Hallucination, auditory 41.80 39.98 18 2588 20675 79721107

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AH01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Neuraminidase inhibitors
FDA MoA N0000175436 Neuraminidase Inhibitors
FDA EPC N0000175524 Neuraminidase Inhibitor
CHEBI has role CHEBI:22587 antiviral agents
CHEBI has role CHEBI:52425 acetylneuraminidase inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Influenza indication 6142004 DOID:8469
Delirium contraindication 2776000
Bronchospasm contraindication 4386001
Hallucinations contraindication 7011001
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Feeling agitated contraindication 24199005
Seizure disorder contraindication 128613002
Impaired cognition contraindication 386806002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.46 acidic
pKa2 12.0 acidic
pKa3 13.81 acidic
pKa4 13.85 acidic
pKa5 9.82 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sialidase 3 Enzyme IC50 5.17 CHEMBL
Sialidase 2 Enzyme Ki 4.77 CHEMBL
Sialidase-4 Enzyme Ki 4.58 CHEMBL
Neuraminidase Enzyme INHIBITOR IC50 9.30 CHEMBL CHEMBL
Neuraminidase Enzyme INHIBITOR Ki 10 CHEMBL CHEMBL
Neuraminidase Enzyme IC50 8.58 CHEMBL
Neuraminidase Enzyme Ki 9.30 CHEMBL
Neuraminidase Enzyme Ki 9 CHEMBL
Neuraminidase Enzyme Ki 9.40 CHEMBL
Neuraminidase Enzyme Ki 9.30 CHEMBL
Neuraminidase Enzyme IC50 7.64 CHEMBL
Neuraminidase Enzyme IC50 8.54 CHEMBL
Neuraminidase Enzyme IC50 5.85 CHEMBL
Neuraminidase Enzyme IC50 8.13 CHEMBL
Neuraminidase Enzyme IC50 8.05 CHEMBL
Neuraminidase Enzyme IC50 8.47 CHEMBL
Neuraminidase Enzyme IC50 8.76 CHEMBL
Neuraminidase Enzyme IC50 7.64 CHEMBL
Neuraminidase Enzyme IC50 8.40 WOMBAT-PK
Neuraminidase Enzyme Kd 8.33 CHEMBL
Neuraminidase Enzyme IC50 8.62 CHEMBL

External reference:

IDSource
4021167 VUID
N0000148618 NUI
D00902 KEGG_DRUG
4021167 VANDF
C0216660 UMLSCUI
CHEBI:50663 CHEBI
ZMR PDB_CHEM_ID
CHEMBL222813 ChEMBL_ID
CHEMBL1673195 ChEMBL_ID
DB00558 DRUGBANK_ID
D053243 MESH_DESCRIPTOR_UI
60855 PUBCHEM_CID
12307 IUPHAR_LIGAND_ID
7272 INN_ID
551942-41-7 SECONDARY_CAS_RN
L6O3XI777I UNII
261633 RXNORM
31156 MMSL
8261 MMSL
d04443 MMSL
007857 NDDF
116100000 SNOMEDCT_US
1217563005 SNOMEDCT_US
387010007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
RELENZA HUMAN PRESCRIPTION DRUG LABEL 1 0173-0681 POWDER 5 mg RESPIRATORY (INHALATION) NDA 26 sections
RELENZA HUMAN PRESCRIPTION DRUG LABEL 1 0173-0681 POWDER 5 mg RESPIRATORY (INHALATION) NDA 26 sections
RELENZA HUMAN PRESCRIPTION DRUG LABEL 1 0173-0681 POWDER 5 mg RESPIRATORY (INHALATION) NDA 26 sections
RELENZA HUMAN PRESCRIPTION DRUG LABEL 1 54868-4377 POWDER 5 mg RESPIRATORY (INHALATION) NDA 25 sections
RELENZA HUMAN PRESCRIPTION DRUG LABEL 1 68258-3030 POWDER 5 mg RESPIRATORY (INHALATION) NDA 25 sections